Growth Metrics

Gilead Sciences (GILD) EBT Margin (2009 - 2026)

Gilead Sciences posted quarterly EBT Margin of 37.07% for Q1 2026, up 1234.0% year-on-year from 2.78% in Q1 2025, and up 41.37% on a QoQ basis from 26.22% in Q4 2025.

Gilead Sciences (GILD) has 18 years of EBT Margin data on file, last reported at 37.07% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin rose 1234.0% year-over-year to 37.07%; the trailing twelve-month figure through Mar 2026 stood at 36.08% (up 1233.0% YoY), and the FY2025 full-year result was 33.27%, up 3087.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 37.07%, up from 26.22% in the prior quarter.
  • Across five years, EBT Margin topped out at 46.87% in Q3 2025 and bottomed at 67.1% in Q1 2024.
  • The 5-year median for EBT Margin is 26.22% (2025), against an average of 21.02%.
  • The widest annual swing landed in 2024, when EBT Margin slumped 8756 bps; it then surged 9183 bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 27.49% in 2022, then slipped by 15 bps to 23.24% in 2023, then climbed by 23 bps to 28.63% in 2024, then declined by 8 bps to 26.22% in 2025, then soared by 41 bps to 37.07% in 2026.
  • The last three EBT Margin figures came in at 37.07% (Q1 2026), 26.22% (Q4 2025), and 46.87% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 44.70%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 24.89%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 6.93%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -21.49%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 24.18%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 37.07%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 135.53%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 28.20%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 37.07%
Dec 31, 2025 26.22%
Sep 30, 2025 46.87%
Jun 30, 2025 34.30%
Mar 31, 2025 24.73%
Dec 31, 2024 28.63%
Sep 30, 2024 12.67%
Jun 30, 2024 29.52%
Mar 31, 2024 -67.10%
Dec 31, 2023 23.24%
Sep 30, 2023 32.87%
Jun 30, 2023 24.06%
Mar 31, 2023 20.47%
Dec 31, 2022 27.49%
Sep 30, 2022 34.54%
Jun 30, 2022 24.01%
Mar 31, 2022 -2.31%
Dec 31, 2021 10.48%
Sep 30, 2021 46.33%
Jun 30, 2021 29.23%
Mar 31, 2021 35.25%
Dec 31, 2020 24.44%
Sep 30, 2020 12.54%
Jun 30, 2020 -57.81%
Mar 31, 2020 36.10%
Dec 31, 2019 32.34%
Sep 30, 2019 -26.78%
Jun 30, 2019 42.39%
Mar 31, 2019 44.50%
Dec 31, 2018 17.53%
Sep 30, 2018 47.61%
Jun 30, 2018 36.93%
Mar 31, 2018 39.96%
Dec 31, 2017 35.74%
Sep 30, 2017 56.37%
Jun 30, 2017 57.62%
Mar 31, 2017 55.60%
Dec 31, 2016 53.55%
Sep 30, 2016 57.01%
Jun 30, 2016 56.57%
Mar 31, 2016 57.76%
Dec 31, 2015 63.92%
Sep 30, 2015 65.97%
Jun 30, 2015 66.85%
Mar 31, 2015 68.99%
Dec 31, 2014 57.83%
Sep 30, 2014 55.79%
Jun 30, 2014 65.89%
Mar 31, 2014 58.99%
Dec 31, 2013 35.66%
Sep 30, 2013 38.80%
Jun 30, 2013 38.87%
Mar 31, 2013 37.13%
Dec 31, 2012 39.50%
Sep 30, 2012 39.19%
Jun 30, 2012 40.31%
Mar 31, 2012 29.30%
Dec 31, 2011 37.21%
Sep 30, 2011 45.95%
Jun 30, 2011 45.97%
Mar 31, 2011 45.41%
Dec 31, 2010 40.00%
Sep 30, 2010 49.60%
Jun 30, 2010 51.53%
Mar 31, 2010 55.60%
Dec 31, 2009 52.13%
Sep 30, 2009 49.47%
Jun 30, 2009 45.87%
Mar 31, 2009 52.00%